Scientific Sessions 2025  /  Inflammation in Preclinical vs. Clinical PAH – A Provocative Debate  /  Debate: Targeting Inflammation is a Viable Therapeutic Avenue for PAH
Logo

American Heart Association

  27
  0

Final ID:

Debate: Targeting Inflammation is a Viable Therapeutic Avenue for PAH

  • Rabinovitch, Marlene  ( STANFORD UNIVERSITY SCHOOL MED , Stanford , California , United States )
  • Stenmark, Kurt  ( UNIVERSITY COLORADO ANSCHUTZ CAMPUS , Aurora , Colorado , United States )
  • Tuder, Rubin  ( UNIVERSITY COLORADO ANSCHUTZ CAMPUS , Aurora , Colorado , United States )
    • Author Disclosures:
    Marlene Rabinovitch: DO have relevant financial relationships ; Advisor:AMGEN:Active (exists now) ; Other (please indicate in the box next to the company name):tiakis receive compound for clinical trial:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Pfizer:Past (completed) | Kurt Stenmark: No Answer | Rubin Tuder: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Inflammation in Preclinical vs. Clinical PAH – A Provocative Debate

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Inflammation and Pulmonary Vascular Remodeling: Cause or Consequence?

Kuebler Wolfgang, Yu Yen-rei, Prins Kurt

Inflammation and Right Ventricular Failure : Is This the Missing Link?

Pullamsetti Soni Savai, Prisco Sasha, Bogaard Harm

More abstracts from these authors:
Epigenetic Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Hypertension

Hadri Lahouaria, Stenmark Kurt, Goncharova Elena, Bonnet Sebastien

Single-Cell Imaging Maps Inflammatory Cell Subsets to Pulmonary Hypertension Vasculopathy

Rabinovitch Marlene, Yuan Ke

You have to be authorized to contact abstract author. Please, Login
Not Available